|
Gene: CLVS1 |
Gene summary for CLVS1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CLVS1 | Gene ID | 157807 |
Gene name | clavesin 1 | |
Gene Alias | C6orf212L | |
Cytomap | 8q12.2-q12.3 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q8IUQ0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
157807 | CLVS1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 8.07e-52 | 9.87e-01 | 0.0155 |
157807 | CLVS1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.30e-15 | 8.46e-01 | -0.1808 |
157807 | CLVS1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 6.94e-06 | 6.25e-01 | 0.0216 |
157807 | CLVS1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.49e-29 | 1.33e+00 | -0.0811 |
157807 | CLVS1 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.46e-58 | 1.80e+00 | -0.1088 |
157807 | CLVS1 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.54e-41 | 1.18e+00 | -0.1954 |
157807 | CLVS1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.10e-07 | 6.28e-01 | -0.1207 |
157807 | CLVS1 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.72e-10 | 6.68e-01 | -0.1526 |
157807 | CLVS1 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.25e-23 | 6.08e-01 | -0.1464 |
157807 | CLVS1 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.28e-10 | 3.98e-01 | -0.1001 |
157807 | CLVS1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.52e-28 | 1.08e+00 | -0.059 |
157807 | CLVS1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.16e-10 | 8.68e-01 | -0.1706 |
157807 | CLVS1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 5.01e-11 | 7.80e-01 | -0.2061 |
157807 | CLVS1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 5.23e-04 | 5.35e-01 | -0.1462 |
157807 | CLVS1 | HTA11_546_2000001011 | Human | Colorectum | AD | 3.29e-08 | 5.28e-01 | -0.0842 |
157807 | CLVS1 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.33e-23 | 1.19e+00 | -0.0179 |
157807 | CLVS1 | HTA11_866_3004761011 | Human | Colorectum | AD | 9.09e-62 | 1.46e+00 | 0.096 |
157807 | CLVS1 | HTA11_4255_2000001011 | Human | Colorectum | SER | 5.11e-17 | 1.44e+00 | 0.0446 |
157807 | CLVS1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 9.23e-27 | 1.34e+00 | 0.0528 |
157807 | CLVS1 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.39e-17 | 1.00e+00 | 0.0131 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | |
Skin | AK | |
Skin | SCCIS | |
Skin | cSCC | |
Thyroid | HT |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0007033 | Colorectum | AD | vacuole organization | 53/3918 | 180/18723 | 4.18e-03 | 2.89e-02 | 53 |
GO:00070331 | Colorectum | MSS | vacuole organization | 48/3467 | 180/18723 | 4.32e-03 | 3.07e-02 | 48 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CLVS1 | SNV | Missense_Mutation | c.1045C>G | p.Pro349Ala | p.P349A | Q8IUQ0 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.94) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |
CLVS1 | SNV | Missense_Mutation | c.154G>A | p.Asp52Asn | p.D52N | Q8IUQ0 | protein_coding | tolerated(0.18) | benign(0.115) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
CLVS1 | SNV | Missense_Mutation | novel | c.523N>T | p.Leu175Phe | p.L175F | Q8IUQ0 | protein_coding | tolerated(0.07) | benign(0.356) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CLVS1 | SNV | Missense_Mutation | rs775886309 | c.934T>A | p.Ser312Thr | p.S312T | Q8IUQ0 | protein_coding | tolerated_low_confidence(0.49) | benign(0.012) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
CLVS1 | SNV | Missense_Mutation | c.221N>T | p.Ala74Val | p.A74V | Q8IUQ0 | protein_coding | tolerated(0.11) | possibly_damaging(0.794) | TCGA-MU-A51Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CLVS1 | SNV | Missense_Mutation | rs368485692 | c.208N>T | p.Arg70Cys | p.R70C | Q8IUQ0 | protein_coding | tolerated(0.11) | benign(0.17) | TCGA-A6-5666-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CLVS1 | SNV | Missense_Mutation | c.10N>T | p.Val4Phe | p.V4F | Q8IUQ0 | protein_coding | deleterious_low_confidence(0.02) | benign(0.006) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CLVS1 | SNV | Missense_Mutation | c.737N>C | p.Lys246Thr | p.K246T | Q8IUQ0 | protein_coding | tolerated(0.08) | possibly_damaging(0.698) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CLVS1 | SNV | Missense_Mutation | rs781486942 | c.301C>T | p.Arg101Cys | p.R101C | Q8IUQ0 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CLVS1 | SNV | Missense_Mutation | rs778256447 | c.781N>A | p.Leu261Ile | p.L261I | Q8IUQ0 | protein_coding | tolerated(0.39) | benign(0.166) | TCGA-AA-A01Z-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |